相关实验视频
Updated: Jun 6, 2025

Engineering Antiviral Agents via Surface Plasmon Resonance
Published on: June 14, 2022
针对SARS-CoV-2变体的受体结合域的化学可以抑制ACE2相互作用
Pisit Ubonsri1, Jiraporn Panmanee1, Ittipat Meewan1
1Institute of Molecular Biosciences, Mahidol University, Salaya, Nakhon Pathom, Thailand.
研究人员确定了两个,Trx-RB9和Trx-RB10,它们与SARS-CoV-2受体结合域 (RBD) 的保留区域结合,跨变体. 这些可以通过阻断ACE2与Omicron变种尖端蛋白结合来抑制病毒的进入.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 药物发现 药物发现 药物发现
背景情况:
- SARS-CoV-2尖峰 (S) 蛋白的受体结合域 (RBD) 对于病毒的进入至关重要,也是疫苗和治疗的关键目标.
- 尽管存在病毒突变,但RBD内的保护区域仍然是目标,为广泛的抗病毒开发提供了机会.
研究的目的:
- 通过SARS-CoV-2变种识别可以结合保存的RBD区域的.
- 为了评估这些已识别的的中和潜力.
主要方法:
- 菌体显示库选确定了RBD结合菌体.
- 选择的 (Trx-RB9,Trx-RB10) 被测试了与各种SARS-CoV-2变体的结合,包括Omicron.
- 分子对接分析了结合部位,中和试验评估了ACE2结合抑制.
主要成果:
- 两个,Trx-RB9和Trx-RB10,证明了与多个SARS-CoV-2变体的RBDs的结合.
- 这些与无活化的SARS-CoV-2和Omicron三元体S结合,EC50值为111.9nM和360.2nM.
- 对Trx-RB9和Trx-RB10的组合抑制了78%的ACE2与Omicron三元体S结合.
结论:
- 化学酸Trx-RB9和Trx-RB10有效地与SARS-CoV-2 RBD跨变体结合.
- 这些抑制了ACE2与Omicron变种RBD的相互作用,表明了中和潜力.
更多相关视频
08:07Author Spotlight: Advancing Antiviral Strategies Through Novel Immunocapture and Mass Spectrometry Techniques
Published on: January 12, 2024
07:53A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation
Published on: January 9, 2019
相关概念视频
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors